Ultragenyx Pharmaceutical Inc. (RARE)
USD 42.94
(-4.47%)
USD 42.94
(-4.47%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 434.24 Million | 363.32 Million | 351.4 Million | 271.03 Million | 103.71 Million | 51.49 Million |
| Cost of Revenue | 45.2 Million | 28.32 Million | 16 Million | 6.12 Million | 9 Million | 1.14 Million |
| Gross Profit | 389.04 Million | 335 Million | 335.39 Million | 264.9 Million | 94.7 Million | 50.34 Million |
| Operating Expenses | 958.24 Million | 983.92 Million | 717.13 Million | 595.01 Million | 518.87 Million | 421.72 Million |
| Selling, General and Administrative Expenses | 309.79 Million | 278.13 Million | 219.98 Million | 182.93 Million | 161.52 Million | 127.72 Million |
| Research and Development Expenses | 648.44 Million | 705.78 Million | 497.15 Million | 412.08 Million | 357.35 Million | 293.99 Million |
| Other Expenses | - | 9.5 Million | 241 Thousand | 7.64 Million | 12.45 Million | 3.95 Million |
| Cost and Expenses | 1 Billion | 1.01 Billion | 733.14 Million | 601.14 Million | 527.88 Million | 422.86 Million |
| Operating Income | -569.2 Million | -648.91 Million | -381.73 Million | -330.11 Million | -424.17 Million | -371.37 Million |
| Interest Expense | 66 Million | 43.01 Million | 29.42 Million | 33.29 Million | 1.13 Million | - |
| Income Tax Expense | -1.82 Million | 5.69 Million | 1.04 Million | 1.2 Million | 3.28 Million | 514 Thousand |
| Earnings before Tax | -608.46 Million | -701.72 Million | -452.98 Million | -185.35 Million | -399.44 Million | -197.09 Million |
| Net Income | -606.63 Million | -707.42 Million | -454.02 Million | -186.56 Million | -402.72 Million | -197.61 Million |
| Earnings Per Share Basic | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 |
| Earnings Per Share Diluted | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 |
| Weighted Average Shares Outstanding | 73.54 Million | 69.91 Million | 67.79 Million | 60.84 Million | 56.57 Million | 49.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 73.54 Million | 69.91 Million | 67.79 Million | 60.84 Million | 56.57 Million | 49.77 Million |
| Gross Margin | 0.90 | 0.92 | 0.95 | 0.98 | 0.91 | 0.98 |
| EBIT Margin | -1.19 | -1.76 | -1.09 | -1.19 | -3.97 | -10.52 |
| Profit Margin | -1.40 | -1.95 | -1.29 | -0.69 | -3.88 | -3.84 |
| EBITDA | -516.45 Million | -640.51 Million | -410.32 Million | -139.8 Million | -389.77 Million | -177.55 Million |
| Earnings Before Tax Margin | -1.31 | -1.79 | -1.09 | -1.22 | -4.09 | -7.21 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 147.02 Million | 108.83 Million | 434.24 Million | 127.39 Million | 98.05 Million | 108.3 Million |
| Cost of Revenue | 30.14 Million | 26.37 Million | 45.2 Million | 12.05 Million | 10.98 Million | 9.91 Million |
| Gross Profit | 116.88 Million | 82.45 Million | 389.04 Million | 115.34 Million | 87.06 Million | 98.39 Million |
| Operating Expenses | 233.24 Million | 247.8 Million | 958.24 Million | 237.39 Million | 232.16 Million | 246.35 Million |
| Selling, General and Administrative Expenses | 80.6 Million | 78.16 Million | - | 76.83 Million | 74.91 Million | 81.4 Million |
| Research and Development Expenses | 152.64 Million | 169.64 Million | - | 160.55 Million | 157.24 Million | 164.94 Million |
| Other Expenses | -1.82 Million | -1.6 Million | -337 Thousand | 2.04 Million | 5.18 Million | -1.98 Million |
| Cost and Expenses | 263.38 Million | 274.18 Million | 1 Billion | 249.44 Million | 243.14 Million | 256.26 Million |
| Operating Income | -116.36 Million | -165.34 Million | -569.2 Million | -122.04 Million | -145.09 Million | -147.95 Million |
| Interest Expense | 15.96 Million | 15.84 Million | 66 Million | 17.32 Million | 17.66 Million | 15.37 Million |
| Income Tax Expense | 858 Thousand | 455 Thousand | -1.82 Million | -3.7 Million | 650 Thousand | 732 Thousand |
| Earnings before Tax | -130.74 Million | -170.22 Million | -608.46 Million | -126.89 Million | -158.99 Million | -159.09 Million |
| Net Income | -131.59 Million | -170.68 Million | -606.63 Million | -123.19 Million | -159.64 Million | -159.82 Million |
| Earnings Per Share Basic | -1.52 | -2.03 | - | -1.52 | -2.23 | -2.25 |
| Earnings Per Share Diluted | -1.52 | -2.03 | - | -1.52 | -2.23 | -2.25 |
| Weighted Average Shares Outstanding | 86.58 Million | 84.28 Million | 73.54 Million | 81.11 Million | 71.66 Million | 70.89 Million |
| Weighted Average Shares Outstanding (Diluted) | 86.58 Million | 84.28 Million | 73.54 Million | 81.11 Million | 71.66 Million | 70.89 Million |
| Gross Margin | 0.79 | 0.76 | 0.90 | 0.91 | 0.89 | 0.91 |
| EBIT Margin | -0.73 | -1.44 | - | -0.81 | -1.43 | -1.28 |
| Profit Margin | -0.90 | -1.57 | -1.40 | -0.97 | -1.63 | -1.48 |
| EBITDA | -107.49 Million | -156.5 Million | - | -103.23 Million | -139.91 Million | -138.62 Million |
| Earnings Before Tax Margin | -0.79 | -1.52 | -1.31 | -0.96 | -1.48 | -1.37 |
2941
011090
MILDEF
605116
7501